Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
FDA determined that CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 mg/6 mL (10 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness, which may affect the availability of generic versions.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 26, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) involved with cabazitaxel products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: None specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA officially determined that the drug product was not withdrawn from sale for safety or effectiveness reasons, which may allow ANDA applicants to rely on it as a reference listed drug.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) involved with cabazitaxel products.
What you must do
No immediate action required; monitor for potential ANDA approvals or market changes.
Deadline
None specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.
- Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV
- US-CONGRESS BILLS-119hr10133ih: Fair Prescription Pricing Act of 2026